Skip to main content



Why Are Physicians Silent About Outrageous Drug Prices?

MedPage Today
Jan 14, 2022

This article was written by Dr. Milton Packer, who wonders why physicians are struggling to get their priorities straight.

Read Article

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Rheumatic and autoimmune patients were not

Read Article

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
RheumNow Podcast square

My Podcast Gift (12.24.2021)

Dec 24, 2021

Merry Christmas and Happy Holidays from RheumNow.

Dr. Jack Cush tells his podcast story - the genesis, keys to success and recommendations on how to get into podcasting - for teaching, practice, fun or influence.

Be sure to register for

Read Article
burnout work overworked

Best of 2021: Rheumatologists Rank 2nd in Physician Burnout

Dec 22, 2021

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.

The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical

Read Article
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Dec 21, 2021

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article (keep)

Telehealth Diet and Exercise Benefits Knee Osteoarthritis

Dec 07, 2021

Annals of Internal Medicine has reported the results of a randomized clinical trial showing that telehealth-delivered exercise and diet programs improved pain and function in knee osteoarthritis patients who were overweight.  While both were beneficial, exercise had a greater effect than

Read Article
RheumNow Podcast square

Telemedicine Upside Interview with Dr. Alvin Wells

Dec 03, 2021

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for

Read Article

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Dec 02, 2021

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..

This makes sense when you see that dementia in RA is associated

Read Article

Improving Rheumatology Practice

Nov 22, 2021

How to best book patient appointments in rheumatology clinic? Should these be scheduled every 3 or 4 months regardless of patient status? Should they be scheduled by patient need or disease activity? 

Read Article
RheumNow Podcast square

RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)

Nov 19, 2021

Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription.. But you later find out they did not change, did not fill the prescription.  Why were

Read Article
ACR Best

ACR21 Best Abstracts - Day 1

Nov 07, 2021

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Read Article
Insurance type, not race or distance to care, assoc'd w/ RA dz activity & burden. We need ^ rheums to care for socially deprived, rural, high comorbidity, Medicaid-covered RA pts w/ enhanced reimbursement & access to tx. Abs 0494 #ACR21 #RheumNow @RheumNow
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 06, 2021

Treat-to-Target Works in Gout With No Cardiac Toxicity

Nov 04, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of

Read Article
Telemedicine black computer

Negative Concerns of Telemedicine in Rheumatology

Nov 04, 2021

Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.

Researchers surveyed a total of 1,340 (UK) patients and 111 clinicians 

Read Article

Blacks with Systemic Sclerosis May Have More Severe Disease

Nov 02, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups, and these worrying disparities may

Read Article
RA Hands Difficult deformity

JAK-pot Study: Cycling JAK Inhibitors Effective in Difficult-to-Treat RA

Nov 02, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi

Read Article
vial.infusion.jpg (keep)

Ultra-Low Dose Rituximab Controls Disease Activity in RA

Nov 02, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to

Read Article
steroid prednisone lab

Are You a High or Low Glucocorticoid Prescriber?

Oct 15, 2021

A recent analysis shows thta glucocorticoids (GCs), usually recommended for short-term use in rheumatoid arthritis (RA), are variably used by rheumatologists, and that provider preference is a strong predictors of long-term glucocorticoid use.

Read Article
RheumNow Podcast square

RheumNow Podcast – #ACA: Ask Cush Anything (10.8.2021)

Oct 08, 2021

Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in

Read Article

Prevalence of Arthritis Rising in the USA

Oct 07, 2021

The latest CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million (23.7%) U.S. adults have arthritis, 25.7 million (43.9%) of whom have AAAL. 

Read Article

Tocilizumab and Drug Shortage Headaches

Sep 22, 2021

Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.

Read Article
ACR20 Capitol

ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule

Sep 16, 2021

In comments submitted to the Centers for Medicare and Medicaid Services (CMS), the American College of Rheumatology (ACR) shared its perspective on the CY 2022 Medicare Physician Fee Schedule and Quality Payment Program proposed rule. 


Rheumatology leaders are encouraged by

Read Article
In 2018-2019 Australia spent $136 billion on healthcare with more spent on MSK disorders ($14 billion) than CV Dz ($11.8 billion), cancer ($11.8 billion) & mental Dz ($10.5 billion). CAD, back pain, dementia, COPD & lung cancer caused most $$ burden.

Dr. John Cush @RheumNow( View Tweet )

Sep 01, 2021

EULAR Points on Managing Difficult Rheumatoid Arthritis

Aug 19, 2021

A EULAR task force has promulgated several points to consider in managing difficult-to-treat RA. These "points" are unique in directing the rheumatologist's attention to the potential for misdiagnosis and the impact of comorbid conditions on what is perceived as poorly controlled RA.

Read Article